Pharmacological studies of meisoindigo: absorption and mechanism of action.
Meisoindigo, an indirubin derivative, is a new type of cancer chemotherapeutic agent. It exhibited higher activity against rodent tumors than indirubin itself. Experiments have shown the improved absorption of meisoindigo, compared to indirubin to be one of the major reasons for the enhancement of antitumor activity. Studies on the mechanism of meisoindigo action indicate that it strongly inhibits DNA biosynthesis in tumor cells. Strong inhibition of the drug on assembly of microtubule protein was also obtained. By means of FCM technique the effects of meisoindigo on mouse leukemia L1210 cell cycle were examined. Experimental results showed that under the action of meisoindigo the S phase cells accumulated and the traverse of the cells in G2 + M phase to G1 phase may also be blocked to some extent.
Ji
X J
XJ
Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing.
Liu
X M
XM
Li
K
K
Chen
R H
RH
Wang
L G
LG
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D007211:Indoles / Q000493:pharmacokinetics / Q000494:pharmacology; D051381:Rats
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D007211:Indoles; C047330:N-methylisoindigotin; C027185:indirubin